Compare · LLY vs UTHR
LLY vs UTHR
Side-by-side comparison of Eli Lilly and Company (LLY) and United Therapeutics Corporation (UTHR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and UTHR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.16T, about 52.2x UTHR ($22.24B).
- Over the past year, LLY is up 64.3% and UTHR is up 67.5% - UTHR leads by 3.2 points.
- UTHR has been more active in the news (25 items in the past 4 weeks vs 17 for LLY).
- LLY has more recent analyst coverage (25 ratings vs 20 for UTHR).
- Company
- Eli Lilly and Company
- United Therapeutics Corporation
- Price
- -
- -
- Market cap
- $1.16T
- $22.24B
- 1M return
- -1.03%
- -1.35%
- 1Y return
- +64.34%
- +67.49%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 1999
- News (4w)
- 17
- 25
- Recent ratings
- 25
- 20
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Latest LLY
- Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)
- Director Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)
- Director Fyrwald J Erik was granted 8 shares, increasing direct ownership by 0.01% to 75,418 units (SEC Form 4)
- Director Alvarez Ralph was granted 10 shares, increasing direct ownership by 0.02% to 55,745 units (SEC Form 4)
- EVP & President, LLY Int'l Jonsson Patrik sold $7,638,150 worth of shares (6,500 units at $1,175.10) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 54,147 units (SEC Form 4)
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
Latest UTHR
- Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $135.42 and sold $4,863,730 worth of shares (9,500 units at $511.97) as part of a pre-agreed trading plan (SEC Form 4)
- Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $135.42 and sold $4,924,666 worth of shares (9,500 units at $518.39) as part of a pre-agreed trading plan (SEC Form 4)
- United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
- Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $135.42 and sold $4,949,717 worth of shares (9,500 units at $521.02) as part of a pre-agreed trading plan (SEC Form 4)
- EVP & GENERAL COUNSEL Mahon Paul A exercised 8,300 shares at a strike of $146.03 and sold $4,342,079 worth of shares (8,300 units at $523.14) as part of a pre-agreed trading plan (SEC Form 4)
- Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $135.42 and sold $5,006,104 worth of shares (9,500 units at $526.96) as part of a pre-agreed trading plan (SEC Form 4)
- Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $135.42 and sold $4,898,221 worth of shares (9,500 units at $515.60) as part of a pre-agreed trading plan (SEC Form 4)
- Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $135.42 and sold $4,812,568 worth of shares (9,500 units at $506.59) as part of a pre-agreed trading plan (SEC Form 4)
- Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $135.42 and sold $4,739,664 worth of shares (9,500 units at $498.91) as part of a pre-agreed trading plan (SEC Form 4)
- United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis